Abstract
A novel process for the preparation of two ketomethylenic antifolates, 2-(2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-amino]- phenyl}-2-oxo-ethyl) pentanedioic acid and 2-(2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-phenyl}-2-oxo-ethyl) pentanedioic acid is described herein. Both compounds were compared with methotrexate as inhibitors of human dihydrofolate reductase and thymidylate synthase. The in-vitro and in-vivo results suggest that these novel antifolate inhibitors could potentially constitute effective therapeutic molecules in the treatment of certain cancers and might present a lower toxicity profile than methotrexate.
Keywords: Antifolate inhibitors, Antitumor activity, Cancer therapy, Classic antifolates, Dihydrofolate reductase, Folyl polyglutamate synthetase, Chemical synthesis, Leukemia, Methotrexate, Multitarget antifolate, Non-classic antifolates, Polyglutamates, Thymidylate synthase, Tumor resistance, 2-(2-4-[(2, 4-diamino-pteridin-6-ylmethyl)-amino]-phenyl-2-oxo-ethyl) pentanedioic acid, 2-(2-4-[(2, 4-diamino-pteridin-6-ylmethyl)-methyl-amino]-phenyl-2-oxo-ethyl) pentanedioic acid
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis and Biological Evaluation of Novel Antifolate Analogs as Potential Anticancer Treatment
Volume: 13 Issue: 2
Author(s): Dan F. Stoicescu and Maria Rotaru
Affiliation:
Keywords: Antifolate inhibitors, Antitumor activity, Cancer therapy, Classic antifolates, Dihydrofolate reductase, Folyl polyglutamate synthetase, Chemical synthesis, Leukemia, Methotrexate, Multitarget antifolate, Non-classic antifolates, Polyglutamates, Thymidylate synthase, Tumor resistance, 2-(2-4-[(2, 4-diamino-pteridin-6-ylmethyl)-amino]-phenyl-2-oxo-ethyl) pentanedioic acid, 2-(2-4-[(2, 4-diamino-pteridin-6-ylmethyl)-methyl-amino]-phenyl-2-oxo-ethyl) pentanedioic acid
Abstract: A novel process for the preparation of two ketomethylenic antifolates, 2-(2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-amino]- phenyl}-2-oxo-ethyl) pentanedioic acid and 2-(2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-phenyl}-2-oxo-ethyl) pentanedioic acid is described herein. Both compounds were compared with methotrexate as inhibitors of human dihydrofolate reductase and thymidylate synthase. The in-vitro and in-vivo results suggest that these novel antifolate inhibitors could potentially constitute effective therapeutic molecules in the treatment of certain cancers and might present a lower toxicity profile than methotrexate.
Export Options
About this article
Cite this article as:
F. Stoicescu Dan and Rotaru Maria, Synthesis and Biological Evaluation of Novel Antifolate Analogs as Potential Anticancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020022
DOI https://dx.doi.org/10.2174/1871520611313020022 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Estrogen Receptor Beta (ERβ) Expression in Different Subtypes of Malignant Pleural Mesothelioma
Current Respiratory Medicine Reviews Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry C75, a Fatty Acid Synthase (FAS) Inhibitor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Multidrug Transporters as Drug Targets
Current Drug Targets Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry